ARVN

Arvinas, Inc.

34.92 USD
-0.31 (-0.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arvinas, Inc. stock is up 9.47% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Apr 18:00 17 May, 2024 35.00 CALL 251 14
16 Apr 17:45 17 May, 2024 35.00 CALL 115 303
17 Apr 19:54 19 Jul, 2024 40.00 CALL 148 28
19 Apr 16:32 21 Jun, 2024 35.00 CALL 172 0
24 Apr 14:32 17 May, 2024 35.00 CALL 196 624
24 Apr 14:57 17 May, 2024 30.00 CALL 70 2
24 Apr 15:11 17 May, 2024 30.00 CALL 108 2
24 Apr 16:29 19 Jul, 2024 30.00 CALL 84 6
24 Apr 16:32 19 Jul, 2024 30.00 CALL 202 6
15 May 15:13 21 Jun, 2024 35.00 CALL 100 632

About Arvinas, Inc.

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

  • HC Wainwright & Co.
    Fri May 17, 10:36
    buy
    confirm
  • Wells Fargo
    Thu May 9, 11:56
    buy
    confirm
  • Wedbush
    Wed May 8, 10:14
    buy
    confirm
  • Stifel
    Wed May 8, 09:08
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 8, 08:51
    buy
    confirm